Zeb1-Hdac2-eNOS circuitry identifies early cardiovascular precursors in naive mouse embryonic stem cells by Cencioni, C et al.
Reviewers' comments: 
Reviewer #1 (Remarks to the Author): 
I am generally comfortable with the novel results and conclusion that eNOS/HDAC/Zeb1 
(through destabilization of the Zeb1/chromatin interaction) triggers mesoendodermal 
cardiovascular commitment. Integrated RNA-seq/Chip-seq point to the role of NO/Zeb1 in 
mesodermal differentiation. Expression patterns of eNOS vs. n/iNOS point to the role for 
eNOS after release from stemness. eNOS knockdown blocks mesoendoderm-associated 
genes. HDAC2/Zeb knockdown influenced eNOS expression.  
I suggest a few control experiments to strengthen the mechanistic aspects of the paper. 
1. Please employ an nNOS inhibitor to exclude complementary effects of nNOS.
2. What effect does a pan NOS inhibitor have cardiovascular commitment?
3. What effect does ODQ have?
4. Mechanistic studies on HDAC nitrosylation are mostly correlative. Please overexpress an
HDAC2 Cys mutant in cells deficient in HDAC to confirm causality. 
Reviewer #2 (Remarks to the Author): 
This manuscript analyzes the transcription profile of nitric oxide (NO) and of Zeb1 in mouse 
stem (mES) cells. Cencioni et al claim that their work identified NO-dependent Zeb1 targets 
and that they isolated an early mES population that synthesizes NO and is enriched in 
mesodermal precursors committed to cardiovascular differentiation. The authors also 
conclude that their results support a role for Zeb1 as repressor of mesodermal 
differentiation and that NO, through its effect on the S-nitrosylation of HDAC2, overcomes 
Zeb1 repressor action.  
General comments 
The work suffers from a number of important shortcomings detailed below. But the main 
criticism is that the conclusions raised by the authors are not supported by the experimental 
data. In fact, the authors have not performed the experiments required to reach those 
claims (see below). For instance, one of the major conclusions of the paper (included in the 
title) is that Zeb1 identifies and regulates key genes in ES cells. As discussed below, the 
authors failed to obtain an efficient CRISP / Cas9 targeting of Zeb1. Even more surprisingly, 
the resulting targeted cells were not used to study the role of Zeb1 in differentiation or in 
the regulation of the selected genes. In addition, none of those genes were validated for 
direct Zeb1 regulation. The manuscript also overlooks several publications directly related to 
the topic.  
Lastly, the manuscript contains numerous mistakes in the description of figures, 
numbering/labeling of panels, definition of culture conditions, etc. While these issues are 
Editorial Note: Several images have been redacted to protect copyright. The images can be 
found in the original publications, cited at the end of the figure legends.
usually considered "minor comments," they are not trivial in this work, particularly 
considering the importance of well-defined culture conditions in ES work.  
 
 
Main criticisms  
 
1) The study deals with an interesting topic for which there is a number of published 
articles. The works follows up of previous paper by the same authors (that surprisingly it is 
not cited) in Spallotta et al (2010) Stem Cells, 28:431-42. The manuscript also overlooks 
two articles directly related to the topic, namely: Mora-Castilla et al (2010). Cell Death & 
Diff, 17:1025-1033 and Tejedo et al (2010). Cell Death & Disease 1:e80. In their discussion 
of Mesp2 and Zeb1, authors should also cite and discuss J Cell Biol (2016) 4:463-7. There is 
also evidence in the literature that Zeb1 is not regulated by NO in epithelial but these works 
are not cited either.  
 
2) The definition of the media and culture conditions is confusing. In addition, in several 
experiments, some culture conditions are not included without explanation (see points 3 and 
4). Obviously, this is a key issue when working with ES. For instance in line 66, authors 
indicated that they use FCS but in Methods they talk about FBS. In other example, two 
different culture conditions are labeled with the same name. In line 72-73: "in response to 
LIF withdrawal (DMSMNO), an effect further enhanced in the presence of NO (DMSMNO)". 
One has to assume that it is meant DMSM but this mistake only adds to the confusion.  
 
3) In Supplemental Figure 1, the authors show the differences between SM and GS cultures 
with regard to NO production. However, they do not measure NOs levels before NONOate 
administration as well as after 24hrs of NONOate administration.  
 
 
4) In Supplemental Figure 2a, the levels of Zeb1 under SM culture conditions should be 
shown.  
 
5) Authors claimed that in Supplemental Figure 2, panel b, DMGSNO "Zeb1 clearly relocate 
out the nucleus". Despite the authors claim that Zeb1 "clearly" relocates, I am not 
convinced by the data shown. At best, this figure only confirms the decrease in Zeb1 
expression shown in "panel a" but the relocation of Zeb1 is not convincing. Most cells in the 
DMGSNO condition express little Zeb1 (if any at all). In sum, their data do not allow to 
conclude that Zeb1 is translocated. Such claim should be backed up by a western blot of 
nuclear and cytoplasmic fractions.  
 
6) Figure 3, panel a. It is not clear why the authors do not shown the DMGSNO condition at 
1 h and 2h as they show these time points for the other culture conditions. The explanation 
of this Figure in the main text (line 163) indicates "gray stripped bars" but there are not 
gray stripped bars in Figure 3, panel a.  
 
7) The efficiency of CRISP/Cas9 targeting of Zeb1 in Supplemental Fig 4c is very poor and 
questions the conclusions that authors make out of the targeting experiments. It would be 
essential to obtain better deletion of Zeb1 (see also below).  
 
8) Supplemental Fig 3b shows that Zeb1 was enriched in selected genes in the GS culture 
condition. Surprisingly, none of these genes is examined with the CRISP/Cas 9 targeted 
cells (LCv2_Zeb1_1 and LCv2_Zeb1_2). In addition, regulation of these genes by Zeb1 
should be validated by quantitative PCR.  
 
9) Very importantly, and key to justify their conclusions: the authors should analyze the 
differentiation genes in Figures 3 panel g and Figure 5 using the cells CRISP/Cas9 targeted 
for Zeb1 and Hdac2 and under the different culture conditions (GS, DMGS, DMGSNO). 
Likewise, they should examine the expression of these genes in the cells targeted for Zeb1 
and Hdac2 with overexpression of eNOs. Without those experiments, it is difficult to claim 
that Zeb1 is regulating these genes, let alone including such claim in the abstract and title 
of the manuscript.  
 
10) Authors should both characterize Zeb1 expression and effect of Zeb1 elimination in 
eSNO- and eSNO+ cells.  
 
11) It should be demonstrated that the elimination of Zeb1 in eSNO- cells increases 
differentiation and miR-200 levels. In addition, miR-200 should be knockdown in eSNO+ 
cells to inhibit differentiation  
 
12) Zeb1 should be overexpressed and examine the number of beating EBs formed  
.  
13) My understanding is that Zeb1 knock out mice does not have defects in cardiovascular 
development (Takagi et al., Development 125, 21-31,1998). Authors should at least discuss 
how their results fit with the phenotype of these mice. In light of the phenotype of the Zeb2 
knock out mice, I feel it is unlikely that this could be explained either by compensation 
between Zeb1 and Zeb2  
 
 
Other comments  
 
1) Several figures and panels are mislabeled. This is particularly the case of Figure 4. The 
panels explained and referred in the main text (lines 215-219) do not correspond to the 
panels shown in Figure 4.  
 
2) While Supplemental Figures are numbered and labeled, the main Figures (at least the 
version that this Reviewer received) are not  
 
3) There is no information about the identity of the Ab used in the Zeb1 ChIP-seq, beyond 
that is a Santa Cruz antibody. This is a highly relevant piece of information considering that 
the quality of the Ab used is essential in ChIP-seq analysis.  
 
4) Line 253. The correct name of the GSK3 inhibitor is CHIR, not CHYR.  
 6) Mouse gene HDAC2 should be written as Hdac2  





Reviewer #1  
 
I am generally comfortable with the novel results and conclusion that eNOS/HDAC/Zeb1 (through destabilization of the 
Zeb1/chromatin interaction) triggers mesoendodermal cardiovascular commitment. Integrated RNA-seq/Chip-seq point to 
the role of NO/Zeb1 in mesodermal differentiation. Expression patterns of eNOS vs. n/iNOS point to the role for eNOS after 
release from stemness. eNOS knockdown blocks mesoendoderm-associated genes. HDAC2/Zeb knockdown influenced 
eNOS expression.  
 
I suggest a few control experiments to strengthen the mechanistic aspects of the paper.  
 
The authors would like to thank the Reviewer for His/Her positive comments to their work. 
 
Q1. Please employ an nNOS inhibitor to exclude complementary effects of nNOS. 
 
A1. The authors thank the Reviewer for the important suggestion. However, in light of the evidence that the specific nNOS 
inhibitor Nω-propil-L-Arginine has been reported as not fully selective for nNOS at least in an in vivo context (Gowda C, 
Toomayan GA, Qi WN, Chen LE, Cai Y, Allen DM, Seaber AV, Urbaniak JR. The effects of N(omega)-propyl-L-arginine on 
reperfusion injury of skeletal muscle. Nitric Oxide. 2004 Aug;11(1):17-24), we decided to address the question about the 
contribution of nNOS in the early NO production of ES further analysing mES where endogenous eNOS was inactivated by 
CRISPR/Cas9 technology. These experiments indicate that the most important effector of endogenous NO synthesis is 
actually eNOS. Its inactivation, in fact, determined a significant drop in NO synthesis after release from stemness in spite of 
a well detectable presence of nNOS. The new data have been now provided respectively in figure 5, panel a and suppl. fig. 
4, panel d of the revised manuscript version. 
 
Q2. What effect does a pan NOS inhibitor have cardiovascular commitment? 
 
A2. The pan-inihibitor L-NAME has been used to address this question. Data indicate that in the presence of this pan-
inhibitor the production of cGMP is abrogated in early released ES cells and the expression of eNOS, Wnt3, Dll1 and Wnt7b 
is significantly reduced. These results are now depicted respectively in figure 3 panel a and suppl. Fig. 4 panel c. 
 
Q3. What effect does ODQ have? 
 
A3. The GC inhibitor ODQ has been used to monitor the early ES production of NO. Figure 3 panel a shows that ODQ 
prevents cGMP synthesis in ES released from stemness. However expression analysis shown in suppl. Fig. 4, panel c 
indicates that ODQ does not interfere with mesendodermal marker expression. These results suggest that cGMP synthesis 
may not be crucial for the NO downstream effect on Zeb1 target gene expression. A specific comment has been reported in 
the Results section of the revised manuscript at page 11 in the paragraph entitled “eNOS is important for mesendodermal 
gene expression”.  
 
Q4. Mechanistic studies on HDAC nitrosylation are mostly correlative. Please overexpress an HDAC2 Cys mutant in 
cells deficient in HDAC to confirm causality. 
 
A4. The authors would like to thank Reviewer for the important suggestion. New experiments have been performed in the 
attempt of providing a role for the Hdac2 cys mutant. The results indicate that the double mutant Hdac2C262A/C274A is poorly 
associated to Zeb1 (figure 3, panel e), thus reproducing the effect of nitrosylation. This result suggests that the cysteines 
modified by nitrosylation are also important for Hdac2:Zeb1 interaction. However the evidence that in absence of the specific 
cysteines or in the presence of nitrosylation Zeb1:Hdac2 association decreases prevented us from performing further 
analysis. 
 
Reviewer #2  
 
The authors would like to thank the Reviewer for His&Her useful comments. The following are their point/to/point answers to 
Reviewer questions. 
 
This manuscript analyzes the transcription profile of nitric oxide (NO) and of Zeb1 in mouse stem (mES) cells. Cencioni et al 
claim that their work identified NO-dependent Zeb1 targets and that they isolated an early mES population that synthesizes 
NO and is enriched in mesodermal precursors committed to cardiovascular differentiation. The authors also conclude that 
their results support a role for Zeb1 as repressor of mesodermal differentiation and that NO, through its effect on the S-
nitrosylation of HDAC2, overcomes Zeb1 repressor action. 






Q1.The work suffers from a number of important shortcomings detailed below. But the main criticism is that the 
conclusions raised by the authors are not supported by the experimental data. In fact, the authors have not 
performed the experiments required to reach those claims (see below). For instance, one of the major conclusions 
of the paper (included in the title) is that Zeb1 identifies and regulates key genes in ES cells.  
 
A1.  The authors would like to thank the Reviewer for giving us the possibility to clarify our findings. Specifically, figure 2, 
panel b clearly shows the presence of Zeb1 binding sites (blue color peaks) on mesendodermal genes identified by 
intersecting RNA-Seq and ChIP-Seq (figure 2, panel a): namely Wnt3, Wnt7b, Dll1, Tbx4 and Mesp2. Moreover, suppl. fig. 
3, panel b shows the results of VALIDATION experiments performed by ChIP/qRT-PCR analysis. These experiments added 
further information about the presence of Zeb1 binding sites on those genes: Zeb1 binding is significantly weakened by the 
release of mES from ground state into differentiation.  
 
Q2. As discussed below, the authors failed to obtain an efficient CRISP / Cas9 targeting of Zeb1. Even more 
surprisingly, the resulting targeted cells were not used to study the role of Zeb1 in differentiation or in the 
regulation of the selected genes. In addition, none of those genes were validated for direct Zeb1 regulation.  
 
A2. We agree that CRISPR/Cas9 targeting of Zeb1 was apparently less efficient than that of Hdac2 and eNOS. However, 
this is the consequence of analyses performed in uncloned bulk cell populations. Nevertheless, we would like to raise the 
Reviewer attention on the fact that two independent targeting constructs were always used in our experiments and, most 
importantly, on the fact that a clear phenotype emerged in spite of the apparent partial Zeb1 targeting. However, in the 
revised manuscript version new experiments were performed to address this specific point. Different clones of Zeb1 
CRISPR/Cas9 mES have been isolated and analysed (suppl. fig. 4, panel a left). The results are shown in the new figure 4, 
panel a indicating that in the presence of Zeb1 knockdown the expression of the mesendodermal genes was upregulated in 
ground state culture compared to control cells. As suggested by the Reviewer, the regulation of these genes has now been 
studied in Zeb1 knockdown cells and in all the experimental conditions tested.  
 
Q3. Lastly, the manuscript contains numerous mistakes in the description of figures, numbering/labeling of panels, 
definition of culture conditions, etc. While these issues are usually considered "minor comments," they are not 
trivial in this work, particularly considering the importance of well-defined culture conditions in ES work. 
 
A3. The authors thank the Reviewer for pointing out our mistakes. They have been fixed in the current manuscript version. 
 
Q4. The study deals with an interesting topic for which there is a number of published articles. The works follows 
up of previous paper by the same authors (that surprisingly it is not cited) in Spallotta et al (2010) Stem Cells, 
28:431-42. The manuscript also overlooks two articles directly related to the topic, namely: Mora-Castilla et al 
(2010). Cell Death & Diff, 17:1025-1033 and Tejedo et al (2010). Cell Death & Disease 1:e80. In their discussion of 
Mesp2 and Zeb1, authors should also cite and discuss J Cell Biol (2016) 4:463-7. There is also evidence in the 
literature that Zeb1 is not regulated by NO in epithelial but these works are not cited either. 
 
A4. Literature has been updated according to Reviewer’suggestions. Spallotta et al (2010) Stem Cells, 28:431-42 is 
reference number 6; Mora-Castilla et al (2010). Cell Death & Diff, 17:1025-1033 is reference number 3; Tejedo et al (2010). 
Cell Death & Disease 1:e80 is reference number 14; and Chiapparo et al J Cell Biol (2016) 4:463-7 is reference number 36. 
 
Q5. The definition of the media and culture conditions is confusing. In addition, in several experiments, some 
culture conditions are not included without explanation (see points 3 and 4). Obviously, this is a key issue when 
working with ES. For instance in line 66, authors indicated that they use FCS but in Methods they talk about FBS. In 
other example, two different culture conditions are labeled with the same name. In line 72-73: "in response to LIF 
withdrawal (DMSMNO), an effect further enhanced in the presence of NO (DMSMNO)". One has to assume that it is 
meant DMSM but this mistake only adds to the confusion.  
 
A5. The culture conditions adopted in our work are relatively standard, however, in the revised version of the manuscript 
they have been provided in greater detail. Specifically, all the experiments have been performed in FBS while FCS has 
never been used: it has been just a typing error. For clarity a new definition of the experimental conditions adopted has been 
now introduced: SM (standard mediumDMEM+LIF+FBS 10%); GS (Ground stateNDiff N2 B27+GSK3i XVI+MEKi+LIF); 
DM (spontaneous differentiation mediumDMEM+ FBS 10%); NO (mesendodermal differentiation medium DMEM+ FBS 
10%+DETA/NO 250uM). A similar definition has been now added to the Methods section. 
 
Q6. In Supplemental Figure 1, the authors show the differences between SM and GS cultures with regard to NO 





production. However, they do not measure NOs levels before NONOate administration as well as after 24hrs of 
NONOate administration. 
 
A6. The authors would like to apoligize for the misunderstanding. Regarding NO production, in fact, suppl. fig. 1 does not 
address NO production in SM and GS culture conditions. Data represent, instead, the assessment of cellular response to an 
exogenously added source of NO, as also stated in the related supplemental figure legend. The results shown in suppl. fig. 
1 have been generated to provide basis for the ground state (GS) culture condition in all subsequent experiments. 
 
Q7. In Supplemental Figure 2a, the levels of Zeb1 under SM culture conditions should be shown. 
 
A7. Zeb1 level analysis under standard medium (SM) culture conditions has been performed and now shown in the updated 
suppl. fig. 2, panel a left. The effect of SM on mES was not further explored and all subsequent experiments were performed 
in GS, DM or NO conditions.  
 
Q8. Authors claimed that in Supplemental Figure 2, panel b, DMGSNO "Zeb1 clearly relocate out the nucleus". 
Despite the authors claim that Zeb1 "clearly" relocates, I am not convinced by the data shown. At best, this figure 
only confirms the decrease in Zeb1 expression shown in "panel a" but the relocation of Zeb1 is not convincing. 
Most cells in the DMGSNO condition express little Zeb1 (if any at all). In sum, their data do not allow to conclude 
that Zeb1 is translocated. Such claim should be backed up by a western blot of nuclear and cytoplasmic fractions. 
 
A8. Thanks to the Reviewer for the important suggestion. New experiments addressing Zeb1 relocation to the cytoplasm 
have now been added in the new suppl. fig. 2, panel c. The results show that Zeb1 is enriched in the cytoplasm of 
fractionated mES cells exposed to an exogenous source of NO.  
 
Q9. Figure 3, panel a. It is not clear why the authors do not shown the DMGSNO condition at 1 h and 2h as they 
show these time points for the other culture conditions. The explanation of this Figure in the main text (line 163) 
indicates "gray stripped bars" but there are not gray stripped bars in Figure 3, panel a. 
 
A9. In our work the effect of DETA/NO on the endogenous production of cGMP was evaluated in DMGSNO (now renamed NO 
condition in the revised manuscript) merely as an internal control experiment. This point has been clarified in the revised 
manuscript version. We thank the Reviewer for raising the point about the gray stripped bars. However, this has been a 
printing error related to a previous version of the figure. The revised figure 3, panel a now shows the appropriate bar code 
simbols.  
 
Q10. The efficiency of CRISP/Cas9 targeting of Zeb1 in Supplemental Fig 4c is very poor and questions the 
conclusions that authors make out of the targeting experiments. It would be essential to obtain better deletion of 
Zeb1 (see also below). 
 
A10. We thank the Reviewer for the important comment. See answer to question 2 and suppl. fig. 4, panel a left. 
 
Q11. Supplemental Fig 3b shows that Zeb1 was enriched in selected genes in the GS culture condition. 
Surprisingly, none of these genes is examined with the CRISP/Cas 9 targeted cells (LCv2_Zeb1_1 and 
LCv2_Zeb1_2). In addition, regulation of these genes by Zeb1 should be validated by quantitative PCR. 
 
A11. Figure 4, panel a shows the results of new experiments performed following Reviewer’suggestion. As stated in the 
answer to question 2 (see above) we have now verified the effect of Zeb1 knockdown on the mesendodermal gene 
expression. 
 
Q12. Very importantly, and key to justify their conclusions: the authors should analyze the differentiation genes in 
Figures 3 panel g and Figure 5 using the cells CRISP/Cas9 targeted for Zeb1 and Hdac2 and under the different 
culture conditions (GS, DMGS, DMGSNO).  
 
A12. Thanks to Reviewer suggestion we verified the effect of Zeb1 or Hdac2 knockdown on the mesendodermal gene 
expression. The new results are now shown in the revised figure 4. However, we would like to emphasize here that the 
suggested experiments related to Figure 5 are not fully justified. In fact, the genes indicated by the Reviewer are late 
cardiovascular differentiation markers. They are not expressed in an early precursor population. The authors are not 
claiming, in fact, that Zeb1 or Hdac2 is regulating late genes neither made any specific statement in this direction. 
 





Q13.Likewise, they should examine the expression of these genes in the cells targeted for Zeb1 and Hdac2 with 
overexpression of eNOs. Without those experiments, it is difficult to claim that Zeb1 is regulating these genes, let 
alone including such claim in the abstract and title of the manuscript. 
 
A13. The authors would like to apologize for the lack of clarity. However, the suggested experiments are unlikely to be 
justified. In fact, in conditions in which Zeb1 or Hdac2 is knocked-down eNOS appears expressed and well detectable 
already in ground state condition (see figure 3 panel h and i). Nevertheless, in the revised manuscript the authors performed 
new experiments in which wild type eNOS and its constitutively active eNOSS1177D mutant have been overexpressed in mES 
cultured in GS condition (figure 5, panel c). In this condition, Zeb1 is well detectable as shown in suppl. Fig. 2. The results, 
now shown in the new figure 5 panel c, d and e, indicate that eNOS overexpression or that of its constitutively active mutant 
is associated with the presence of mesendodermal gene transcripts detectable in spite of GS suggesting for a positive role 
of eNOS in the regulation of those targets.   
 
Q14. Authors should both characterize Zeb1 expression and effect of Zeb1 elimination in eSNO- and eSNO+ cells.  
 
A14. A new experiment has been performed as shown in the revised panel e of figure 6. The result suggests that, as 
expected, Zeb1 expression is reduced in ESNO+ cells possibily as consequence of miR200b upregulation. Therefore we felt 
no strong rationale to perform an experiment aimed at eliminate Zeb1 from ESNO+ cells. Moreover, CRISPR/cas9 
experiments aimed at targeting Zeb1, shown in the revised figure 3 panel g and figure 4 panel a, indicated that eNOS and 
the mesendodermal genes became already detectable in the presence of GS. Hence, we felt that there was no rationale 
exploring further the role of Zeb1 in ESNO- cells.  
 
Q15. It should be demonstrated that the elimination of Zeb1 in eSNO- cells increases differentiation and miR-200 
levels.  
 
A15. See A14.  
 
Q16. In addition, miR-200 should be knockdown in eSNO+ cells to inhibit differentiation 
 
A16. In order to address the role of miR 200 family in mES cells, we knocked-down miR200b in wild type mES and 
demonstrated that Zeb1 expression remained elevated in differentiatied cells. In the same experiment we observed a 
significant reduction of mesendodermal gene expression as expected in consequence of an elevated Zeb1 cellular content. 
The new data have been now shown respectively in the revised version of suppl. Fig. 2, panel d and suppl. Fig. 3, panel c. 
 
Q17. Zeb1 should be overexpressed and examine the number of beating EBs formed. 
 
A17. Zeb1 is expressed in ESNO- cells (figure 6, panel e) that do not generate beating EBs (figure 6 panel h). Therefore we 
felt no rationale to perform the suggested analysis. However, in order to understand further the effect of Zeb1 on mES 
differentiation we overexpressed the factor in wild type cells and found that they were unable to properly differentiate. 
Specifically, the forced expression of Zeb1 in naïve mES reduced or prevented the expression of mesendodermal markers 
in cells released from stemness and exposed to NO. The results are shown in the new supplemental figure 5 of the revised 
manuscript version. 
 
Q18. My understanding is that Zeb1 knock out mice does not have defects in cardiovascular development (Takagi 
et al., Development 125, 21-31,1998). Authors should at least discuss how their results fit with the phenotype of 
these mice. In light of the phenotype of the Zeb2 knock out mice, I feel it is unlikely that this could be explained 
either by compensation between Zeb1 and Zeb2. 
 
A18. The authors would like to thank the Reviewer for the important suggestion. According to literature Zeb1 KO has an 
effect on neuroectodermal and neural-crest derived structures including some skeletal muscle components (Higashi et al. J 
Exp Med 1997; Takagi et al., Development 1998; Bellon et al., J Cell Biol 2009). Alterations in the cardiovascular system are 
poorly represented and limited to a sporadic hemorrhagic phenotype. The literature related to this point has been 
commented in greter detail in the Discussion section of the present version of the manuscript. This is in line with the 
evidence that Zeb1 physiologically counteracts the mesendodermal differentiation of mES in favour of neuroectodermal 
markers expression. Further, we found that ESNO- Zeb1 positive cells are enriched of neuroectodermal associated genes, 
such as Meis1 and Pax6 (see figure below).   
 






ESNO+ cells are not enriched for neuroectodermal marker expression. mRNA expression analysis of Meis1 and Pax6 in ESNO- (black bars) and 
ESNO+ (white bars) derived EBs taken at different time points of the EB maturation process. Data are shown as mean ±SE  fold increase compared to 




1) Several figures and panels are mislabeled. This is particularly the case of Figure 4. The panels explained and 
referred in the main text (lines 215-219) do not correspond to the panels shown in Figure 4. 
2) While Supplemental Figures are numbered and labeled, the main Figures (at least the version that this Reviewer 
received) are not 
3) There is no information about the identity of the Ab used in the Zeb1 ChIP-seq, beyond that is a Santa Cruz 
antibody. This is a highly relevant piece of information considering that the quality of the Ab used is essential in 
ChIP-seq analysis.  
4) Line 253. The correct name of the GSK3 inhibitor is CHIR, not CHYR.  
6) Mouse gene HDAC2 should be written as Hdac2. 
 




Reviewers' comments:  
 
Reviewer #1 (Remarks to the Author):  
 
The observations are interesting and the manuscript has been improved by the changes.  
 
I have a couple of minor questions and comments  
 
1. Is the effect of NO on PP2A (mentioned in the introduction) mediated by cGMP or S-
nitorsylation (the latter has been reported). It's not clear as written.  
2. Discussion first para, The authors refer to 'a dose effect of NO'. This is a pharmacological 
effect, not physiological. There is little evidence for dose effects of NO in any physiological 




Reviewer #2 (Remarks to the Author):  
 
The revised version of the manuscript has fixed, in some cases without a clear explanation 
of how they did it, some (and only some) of the minor issues. Nevertheless, my main 
concern regarding the lack of novel mechanistic insights with what has been already 
published still holds. The authors continue to overlook important earlier studies on the very 
same topic and to clarify the existing controversies between their findings and some of 
those studies. Lastly, several articles on the role of Zeb1 and Hdac1 (but, importantly, not 
Hdac2) in the differentiation of hESC/iPSC towards cardiomyocytes have been published 
since the original submission over a year ago. However, and once again, the authors failed 
again to cite any of these new works.  
 
1) The study continues to overlook many works directly related to this study and to clarify 
existing controversies. A) PNAS 18:8242 showed that Hdac1, but not Hdac2, is involved in 
the differentiation of embryoid bodies into cardiomyocytes (and in the regulation of Nkx2-5 
and Mef2c). That study found that HDAC1 is required for the reprogramming of ES cells 
upon differentiation and that conditional KO stem cells where Hdac1 and Hdac2 have been 
inactivated, only Hdac1-deficient embryoid bodies showed the spontaneous rhythmic 
contraction and increased expression of both cardiomyocyte and neuronal markers. J Biol 
Chem 280:19682 has also studied the role of HDACs in the differentiation of ES toward 
cardiomyocytes. These studies were not cited. The article in PNAS should be at least 
discussed as it directly relates to this study. B) Links between Hdac, eNOS and Zeb1 have 
been previously reported, not only in Gut 61:329 (cited in the manuscript ), but also in 
EMBO Mol Med. 7:831, Stem Cells 31:1749 and many others. However, these articles were 
not cited or discussed. C) A recent study published in Circulation Research (doi:10.1161/ 
CIRCRESAHA.116.310456) by Snyder's group has elegantly and convincingly shown the role 
of Zeb1 in cardiomyocyte differentiation. Using an RNA-seq of hiPSCs and hESCs during 
cardiomyocyte differentiation, the study in Circulation Research found that ZEB1 is required 
for early cardiomyocyte differentiation. The study goes well beyond this manuscript as it 
shows a much more complex picture of the transcriptomics involved at different stages 
during cardiomyocyte differentiation, such as T and EOMES (mesoderm); LEF1 and MESP1 
(from mesoderm to cardiac mesoderm); MEIS1 and GATA4 (post-cardiac mesoderm); JUN 
and FOS families, and MEIS2 (cardiomyocyte). The manuscript has a clear overlapping with 
this manuscript and authors should cite and discuss this important work. D) Lastly, while 
the authors now cited the four articles I highlighted in the first review, they have not 
engaged in any meaningful discussion on how these articles relate/overlap with their own 
work.  
 
2) I continue to be concerned with the CRISP/Cas9 targeting of Zeb1. In the original 
manuscript (Supplemental Figure 4c) authors failed to obtain an efficient CRISP/Cas9 
targeting of Zeb1 using two independent vectors (GS-LCv2_Zeb1_1 and GS-LCv2_Zeb1_2). 
Now (Supplementary Figure 4a) they show that CRIPS/Cas9 targeting has abrogated Zeb1 
expression but it is not clear whether the CRIPS/Cas9 vector has been changed. The authors 
now referred this vector as LCv2_Zeb1. However, in Methods, the authors still mentioned 
the two vectors used in the original version (GS-LCv2_Zeb1_1 and GS-LCv2_Zeb1_2). One 
has to assume that only one of the original vectors worked. If that In that case, it is not 
clear which of the two vectors is shown in Supplementary Figure 4A and used in Figures 3g 
and 4a. It is not clear which targeting vectors referred in Methods are used in the 
manuscript, why only one of the two (or probably none of them) is shown in Suppl Fig 4c, 
which of the targeting vectors worked or why in Supp Fig 4c one of the targeting vectors 
has been now deleted. In any case, as standard practice (particularly for a journal like 
Nature Communications), at least TWO independent CRIPS/Cas9 targeting vectors for Zeb1 
should be used, particularly considering that Zeb1 is the main point in the title and 
Abstract.  
 
3) Cytoplasmic translocation of Zeb1. In the original version, the authors claimed that in 
Supplemental Figure 2, panel b, Zeb1 “clearly” relocate out the nucleus. A new Supp Fig 2c 
showing Zeb1 expression in cytoplasmic and nuclear fractions has been added. However, 
the authors made no effort to show a more representative immunofluorescence picture. 
Supp Fig 2b continues to be unconvincing at best. In other words, the results in Suppl Fig 
2b and 2c do not match.  
 
4) Figure 6e. The Western blot for Zeb1 in ESNO+ has half of the band stronger than the 
other half as if a bubble interfered with the blotting. Another blot should be shown.  
 
5) For all the Western blots in the manuscript, full uncut gels should be shown. This a 
standard practice nowadays and it becomes critical in this manuscript where many of the 
blots shown were cut just below/above the band or the bands are not very clear (bottom of 
Fig 3e, Fig 5d, Fig 6a, Supp Fig 1b, Supp Fig 2d, Supp Fig 4a, Supp Fig 5a). Full uncut gels 
should be shown for all Western blots.  
 
Minor comments  
 
6) In my first review, I pointed to the need to provide a comprehensive list with the source 
of all the Abs used. This is critical considering that the quality of the Ab used is essential in 
ChIP-seq analysis. The authors indicated that the information has been now included. But 
this reviewer was unable to find (unless I did not get all the manuscript documents) where 
this information has been included. At least, it is not in the section of Methods related to 
Western blot and immunoprecipitation.  
 
Kind suggestion  
 
7) Considering that: a) the data on Zeb1 are the weakest and, for the most part 
unconvincing, b) the article in Circulation Research overlaps with this manuscript and nicely 
defines a role for Zeb1 in cardiomyocyte differentiation, and c) the Hdac1/Hdac2 
controversy (PNAS 18:8242), it is my humble opinion that the manuscript will benefit from 




Reviewer #3 (Remarks to the Author):  
 
Cencioni et al. report that endothelial nitric oxide synthase (eNOS) is rapidly upregulated in 
a subpopulation of mouse ES cells upon exit from ground state pluripotency in 2i/LIF 
conditions. This eNOS-positive fraction produces nitric oxide (NO), shows elevated 
expression of mesendodermal genes and more efficiently generates embryoid bodies with 
beating areas. ES cells in which eNOS was disrupted by CRISPR-mediated gene targeting 
failed to produce NO or efficiently upregulate mesendodermal genes following the 
withdrawal of 2i/LIF. Mechanistically, NO was shown to inhibit the nuclear function of Hdac2 
via S-nitrosylation, and to activate the expression of miR-200 miRNAs. Both of these events 
are proposed to antagonize the transcriptional repressor Zeb1, which normally suppresses 
mesendoderm-associated genes including eNOS under ground state conditions. The 
existence of a feedback circuitry among Zeb1, Hdac2 and eNOS is corroborated by 
additional genetic studies showing that CRISPR-mediated ablation of Zeb1 or Hdac2 in ES 
cells causes premature expression of eNOS and other mesendoderm-associated genes.  
 
This manuscript uncovers a novel regulatory axis mediating mesendodermal commitment of 
ground state mouse ES cells. Previous work had suggested that low doses of NO delay 
differentiation (Tejedo et al., 2010), but this study demonstrates that eNOS/NO promote ES 
cell differentiation, especially into cardiovascular precursors. Overall the manuscript is of 
interest and appropriate for Nature Communications, but the authors should clarify the 
following points:  
 
1. ChIP experiments indicate that Zeb1 becomes uncoupled from chromatin at 
mesendodermal target genes in differentiation media, regardless of whether an exogenous 
source of NO is supplied (Figure S3b). However, the induction of mesendodermal target 
genes was far more dramatic in the presence of exogenous NO (Figure S3a). This raises an 
important question which the authors do not comment on: how does exogenous NO further 
boost the expression of mesendodermal genes? Since Zeb1 is already fully uncoupled from 
chromatin in DM alone, there must be some additional mechanism whereby exogenous NO 
promotes mesendodermal commitment that is independent of Zeb1 (see also my next 
point).  
 2. The authors propose two distinct mechanisms for NO-dependent regulation of 
mesendodermal target genes: S-nitrosylation of Hdac2, which leads to nuclear export of 
Zeb1, and activation of miR-200b, which inhibits Zeb1 translation. While inhibition of miR-
200b abrogates NO-dependent activation of several mesendoderm-associated genes, the 
activation of Wnt3 and Tbx4 was notably less affected (Figure S3c). Interestingly, these two 
mesendodermal targets were not induced in Zeb1-KO ES cells cultured with exogenous NO 
(Figure 4a), but they were highly induced in Hdac2-KO ES cells cultured in the same 
condition (Figure 4b). These observations suggest that Hdac2 mediates transcriptional 
repression at a subset of mesendodermal targets, such as Wnt3 and Tbx3, independently of 
Zeb1. Have the authors considered the possibility of such a Zeb1-independent role of 
Hdac2?  
 
3. As a general point, I wonder how representative the experiments with an exogenous 
source of NO are for the endogenous activation of eNOS/NO that occurs during ES cell 
differentiation. Can the authors directly compare the levels of NO under these two 
experimental conditions? In addition, does the DAF+ subpopulation shown in Figure 6b have 
increased S-nitrosylation of Hdac2 (as was shown in Figure 3c in presence of exogenous 
NO)?  
 
Minor points:  
 
1. Throughout the manuscript CRISPR-targeted ES cell lines should be referred to as 
knockout, rather than knockdown clones. The term “knockdown” is typically used to denote 
RNAi studies where only partial downregulation of the target gene is achieved.  
 
2. Please add in-figure labels to the ChIP-Seq tracks in Figure 2b and Figure S4b.  









Reviewers' comments:  
 
The observations are interesting and the manuscript has been improved by the changes. 
 
The authors would like to thank the Reviewer for His/Her positive comments to their revised 
work 
 
Q1) Is the effect of NO on PP2A (mentioned in the introduction) mediated by cGMP or S-
nitrosylation (the latter has been reported). It's not clear as written.  
A1) The indicated point has been clarified in the Introduction as requested (see Page 5, lines 99-
104). 
Q2) Discussion first para, The authors refer to 'a dose effect of NO'. This is a 
pharmacological effect, not physiological. There is little evidence for dose effects of NO in 
any physiological context. "Dose effects" likely reflect engagement of alternative targets. I 
would remove this statement.  
A2) The specific paragraph in the Discussion section has been amended according to 




Q1) PNAS 18:8242 showed that Hdac1, but not Hdac2, is involved in the differentiation of 
embryoid bodies into cardiomyocytes (and in the regulation of Nkx2-5 and Mef2c). That 
study found that HDAC1 is required for the reprogramming of ES cells upon 
differentiation and that conditional KO stem cells where Hdac1 and Hdac2 have been 
inactivated, only Hdac1-deficient embryoid bodies showed the spontaneous rhythmic 
contraction and increased expression of both cardiomyocyte and neuronal markers. J Biol 
Chem 280:19682 has also studied the role of HDACs in the differentiation of ES toward 
cardiomyocytes. These studies were not cited. The article in PNAS should be at least 
discussed as it directly relates to this study.  
A1) The authors would like to thank the Reviewer for His/Her suggestion about updating the 
relevant literature concerning the role of Zeb1 and Hdacs in their system. However, we would 
like to raise here the point that as stated into the journal instructions to authors the number of 
allowed references is limited. Therefore only the most informative citations have been reported 
so far.  For this reason, in the revised version of our work the indicated PNAS and other few 
references have been added and commented where appropriate. Hence, the suggested J Biol 
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Chem 280:19682 has not been cited in light of the fact that the functional studies described there 
were accomplished by means of the chemical pan-Hdac inhibitor Trichostatin A (TSA) whose 
effect has been matter of prior investigation in our laboratory (see ref. 6 in the revised 
manuscript) and is out of the scope of the present manuscript. Nevertheless, we took great 
advantage from the Referee’ suggested citation of Cowley’s work (PNAS 2010) reporting about 
a distinct role of Hdac1 and 2 in early mouse ES differentiation. The specific reference (now Ref 
number 21) has been added and commented in the Introduction and Discussion sections of the 
revised manuscript (Page 5 lines 108-120; Page 15 lines 433-448). The indicated article deals 
with a very relevant aspect related to the definition of Hdac1 and 2 functional specificities. The 
authors described that Hdac1 inactivation but not that of Hdac2 enhances cardiovascular 
differentiation in mouse ES. This is an interesting report that shed some light on the 
controversial matter of Hdac1/2 redundancy vs. specialized functions (e.g. Montgomery RL 
GENES & DEVELOPMENT 2007, 21:1790–1802; Hagelkruys A. Development 2014, 141: 604-
61; Jamaladdin S. PNAS 2014 8, 111:9840-5). We believe of interest here to point out that 
Hdac1 and 2 share the same co-repressor complexes (see Figure 1).  
Figure 1. A summary of the three main Hdac1/2-containing complexes: Sin3, NuRD and 
CoREST Each complex contains multiple subunits with DNA/chromatin-recognition motifs 
indicated by the color code. In addition, deacetylase and ELM2/SANT domains are also shown. 
The Hdac1/2-binding subunit within each complex, i.e. Sin3A/B, MTA1/2/3 or CoREST1/2/3, 
are shown in bold. (adapted from Biochem. Soc. Trans. (2013) 41, 741–749). 
In consideration of the relatively ubiquitous distribution of these complexes and the complexity 
of their regulatory networks it is conceivable that at least some of Hdac1 and 2 functions could 
be overlapping as well as distinct effects will appear in specific contexts. Indeed the evidence 
provided by Cowley and coworkers does not rule out whether Hdac2 exerts any regulatory 
[redacted]
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functions on Hdac1 (see also Hagelkruys A. et al. Development 2014;141, 604-616) or being 
required for its appropriate activity as also indicated by a more recent work from the same 
authors (see reference 22 in the revised manuscript version). In this regard, it is relevant to point 
out that specific post-translational modifications may occur differentially on Hdac1 and Hdac2 
in spite of a large degree of sequence homology between the two molecules. Specifically, Hdac1 
is acetylated, phosphorylated, SUMOylated and poly-ubiquitinilated while Hdac2 is acetylated, 
phosphorylated, SUMOylated, carbonylated and S-nitrosylated (Figure 2). Notably, Hdac2 and 
Hdac6 are the only Hdacs known to be functionally controlled by nitric oxide trough S-
nitrosylation.  
Figure 2. 
Schematic representation of the PTMs spatial distribution of Hdac1 and Hdac2. (a) Organization 
of the functional domains of Hdac1 and Hdac2. Numbers indicate the corresponding amino 
acidic (aa) positions. Percentages of identity were calculated by BLAST alignment of Hdac1 
(CAG46518.1) and Hdac2 (AAH31055.2) protein sequences. (b) and (c) Visual comparison of 
the diﬀerent PTMs occurring on Hdac1 and Hdac2 in the C-terminal (B) and central (C) 
domains. Diﬀerent PTMs are illustrated by diﬀerent colors and letters: P (yellow): 
phosphorylation, A (green): acetylation, U (blue): ubiquitination, S (red): SUMOylation, N 
(orange): nitrosylation, and C (lilac): carbonylation. The amino acidic sites of modiﬁcation are 
indicated by the number of their position in the protein sequence: S: serine, K: lysine, Y: 
tyrosine, C: cysteine, and CBP: CBP histone acetyltransferase. When the precise position of a 
modiﬁed residue is not known, the amino acidic site is followed by an x. The question mark (?) is 
used when the precise amino acidic site has not been formally identiﬁed. The amino acids at the 
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boundaries of the two domains are reported. (J. Biomed. and Biotechnol 
.doi:10.1155/2011/690848) 
In agreement, our prior work (see references 16 and 19 in the revised manuscript reference list) 
demonstrated that Hdac2 but not Hdac1 is post-translationally modified by nitric oxide-
dependent nitrosylation on cytosines 262 and 274 and that this modification led to Hdac2 
detachment from DNA and functional inactivation. Noteworthy, ref.16 also reports that Hdac2 S-
nitrosylation reduces Hdac1 activity (Figure 3, panels A, B, D, F). 
Figure 3. NO regulates the enzymatic activity of Hdac2 by cysteine-S-nitrosylation. (A) Western 
blotting analysis of Hdac1, Hdac2, and Hdac3 in C2C12 myoblasts after immunoprecipitation 
with anti S-nitroso-cysteine-speciﬁc antibody. An increased cysteine-S  nitrosylation of Hdac2 
was detectable after4h of treatment with DETA-NO. (B) The bar graph shows the Hdac1-, 
Hdac2-, and Hdac3-speciﬁc activity in C2C12 evaluated in the presence or absence of DETA-
NO treatment for 4 h. (C) Anti-S-nitroso-cysteine antibody immunoprecipitation and Western 
blotting analysis of Hdac1, Hdac 2, and Hdac3 in WT and MDX mice infected with either eNOS 
S1177A or GFP adenovirus adductor muscles. An increased cysteine-S-nitrosylation of Hdac2 
was detectable after 14 days from AdeNOS infection. (D) The bar graph shows in vivo the 
Hdac1-, Hdac2-, and Hdac3-associated enzymatic activity evaluated in adenovirus-infected WT 
and MDX mice expressing GFP or eNOS, respectively, in the adductor muscles. Assays were 
performed on total muscle lysates after immunoprecipitation with anti- Hdac1-, anti- Hdac2-, and 
anti- Hdac3-speciﬁc antibodies. (E) Evaluation of NO effect on recombinant E. coli GST-
puriﬁed Hdac1-, Hdac2, and Hdac3-speciﬁc activities in the presence or absence of Hdac 
inhibitor SAHA (SA, 5 _M) or NO donors SNAP (SN, 205 _M) or GSNO (GS, 250 _M). (F) 
Western blotting analysis of S-nitroso-cysteine on recombinant Hdac1 and Hdac2 proteins after 
NO donors SNAP (SN, 10 mM) or GSNO (GS, 10 mM). Data were normalized by densitometry 
analysis (Right). (PNAS 2008, 105:19183-7). 
[redacted]
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In light of this evidence we cannot exclude that Hdac1 could be negatively influenced by the S-
nitrosylation of Hdac2. To further explore this point, in the revised manuscript version, new 
experiments have been provided showing that in experimental conditions in which Zeb1 and 
Hdac2 are detached from chromatin also Hdac1 detaches from the promoter regions of Zeb1 
target genes involved in the regulation of mesendoderm/cardiovascular commitment. The results 
are now shown in suppl. Figure 3 panel c and d suggesting for the presence of a coregulatory 
mechanism among Zeb1, Hdac1 and Hdac2.  
A specific comment addressing this aspect has been included to the revised version of our 
manuscript in which a sentence about a possible indirect and negative effect of NO on Hdac1 
has been added in the Results and Discussion sections (page 10, lines 260-265; page 15 lines 
432-438).  
Q2) Links between Hdac, eNOS and Zeb1 have been previously reported, not only in Gut 
61:329 (cited in the manuscript ), but also in EMBO Mol Med. 7:831, Stem Cells 31:1749 
and many others. However, these articles were not cited or discussed. 
A2) The authors are aware that Zeb1, Hdac1 and 2 interact forming a regulatory complex as 
depicted in Figure 4 functionally relevant in the process of epithelial/mesenchymal transition.   
Figure 4. Zeb1 is an important repressor of the CDH1 gene in pancreatic cancer. In epithelial 
pancreatic cancer cells, transcription of the CDH1 gene, encoding E-cadherin, is activated by a 
multiprotein complex containing transcription factors (TF) which recruit RNA polymerase II 
(Pol II) via a coactivator complex (CAC) to the CDH1 promoter. During the dynamic process of 
epithelial to mesenchymal transition (EMT), the CDH1 gene is epigenetically silenced. One 
pathway involves the transcriptional repressor Zeb1, which recruits Hdac1 and/or Hdac2 
containing corepressor complexes (CRC) to inhibit transcription of the CDH1 gene. Gut 
2012;61:329e330. 
[redacted]
C Cencioni et al. Mechanics of mesendodermal commitment in ground state mES 
6 
However, the interconnection among Zeb1, Hdacs and NOS isoforms is still controversial and 
largely uncharacterized. In a manuscript from Rossig et al (Circ Res. 2002;91:837-44) it is 
reported that eNOS regulation by Hdacs may occur at transcription and post-transcription level 
while no clear association has been made between Zeb1 and eNOS expression (see additional 
comments below).  Regrettably, space limits our possibility to report all the redundant citations 
related to this matter and in our revised manuscript we were forced to make a choice in favor of 
those strictly relevant for our findings. The work of Adhgassi et al on Gut 61:329, is, to our 
knowledge, one of the earliest contribution describing the protein-protein association of Zeb1 
with both Hdac1 and 2. Unfortunately, we could not find a way to cite the work from Meidhof S. 
et al (EMBO Mol.Med. 2015;7:831-47) in our manuscript. This is in consequence of the fact that 
in that study chemical inhibitors of Hdac activity were used to investigate Zeb1 biological 
properties. Their characterization is out of the scope of our present study. In fact, we addressed 
the role of Hdac inhibitors in one of our prior publications on mES (see reference 6 in the 
revised manuscript and figure 5 below).  
Figure 5. HDACi differentially regulate ESC differentiation—immunoﬂuorescence analysis. 
ESCs were deprived of LIF for 24 hours in the presence or absence of HDACi or control solvent 
(DMSO) and double immunoﬂuorescence was performed. (A): This picture shows that TSA and 
MC1568 (specific class II Hdac inhibitor) prevent the spontaneous onset of Flk-1 and Desmin 
while inducing the expression of Nestin. On the contrary, MS27-275 (specific Class I Hdac 
inhibitor) induced the expression of Flk-1 and Desmin. This result is representative of ﬁve 
independent experiments. (B): This picture shows that TSA and MC1568 prevent the 
spontaneous onset of SM22a and Bry. On the contrary, MS27-275 induced the expression of 
these markers. This result is representative of ﬁve independent experiments. (see Spallotta et al 
ref. 6) 
[redacted]
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Specifically, in our prior work (see ref. 6) we reported that class I selective Hdac inhibitors were 
able to activate a mesendodermal differentiation program in mouse ES cells. In the revised 
version of the present manuscript, we updated our reference list including the manuscript from 
Luo et al Stem Cells 31:1749 which, interestingly, demonstrated the high level of expression of 
Zeb1 in undifferentiated hESC and the importance of Zeb1 as repressor of vascular precursor 
commitment in that system. This work is conceptually very close to ours and we reasoned that it 
would really enforce our findings (see also A3 below). In spite of this positive contribution, it is 
worth noting that in Luo’s study the expression of eNOS is merely used as a vascular 
differentiation marker and no mechanistic evidence or associations with Zeb1 or Hdacs has been 
provided. On the opposite, in our manuscript (Figure 3, panel g) data in favor of a direct 
association between Zeb1 and eNOS promoter are provided contributing original information 
about the presence of a possible eNOS-Zeb1 regulatory loop in our system. 
Q3) A recent study published in Circulation Research (doi:10.1161/ 
CIRCRESAHA.116.310456) by Snyder's group has elegantly and convincingly shown the 
role of Zeb1 in cardiomyocyte differentiation. Using an RNA-seq of hiPSCs and hESCs 
during cardiomyocyte differentiation, the study in Circulation Research found that ZEB1 
is required for early cardiomyocyte differentiation. The study goes well beyond this 
manuscript as it shows a much more complex picture of the transcriptomics involved at 
different stages during cardiomyocyte differentiation, such as T and EOMES (mesoderm); 
LEF1 and MESP1 (from mesoderm to cardiac mesoderm); MEIS1 and GATA4 (post-
cardiac mesoderm); JUN and FOS families, and MEIS2 (cardiomyocyte). The manuscript 
has a clear overlapping with this manuscript and authors should cite and discuss this 
important work.  
A3) The authors would like to thank the Reviewer for pointing out this important recent work 
published while our manuscript was under the second round of revision.  The manuscript from 
Liu Q et al (Circ Res. 2017;121:376-391) has now been added to the Bibliography section of our 
revised manuscript as ref number 54. Nevertheless, after careful evaluation the authors 
concluded that, although cleverly performed, the work from Liu et al. had modest impact on their 
findings. In fact, i) Liu’s work has been made in very different cellular systems not directly 
comparable to ours, e.g. human embryonic and human inducible pluripotent stem cells; ii) The 
results from Liu et al. are in apparent contrast with reports previously published by others (see 
below); iii) Consistently, the results of Liu et al are also in contrast with our functional data 
showing that forced expression of Zeb1 prevents/reduces expression of 
mesendodermal/cardiovascular markers as shown in supplemental figure 5. Considering the 
diversity in the experimental settings and the other evidences provided in literature, which are 
instead in agreement with our results, (see point ii listed above and the additional comments 
provided below) no clear explanation is possible at this time about this apparent discrepancy; iv)  
In our work, we aimed first at investigating molecularly  the effect of pharmacological doses of 
nitric oxide on mES ending up with the identification and characterization of an unprecedented 
precursor cell population  autonomously synthetizing NO; v) Liu and coworkers did not address 
this specific point, as they did not perform any experiment to investigate the role of NO during 
differentiation of human iPS and hESC. 
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More in detail, not only Liu’s work is in contrast with our present work but also in contrast with 
data reported in the work of Luo et al ( Stem Cells 31:1749) and that of Kim Y et al (Int J Stem 
Cells. 2017;10:28-37). These other authors, in fact, stated respectively that:  
• “we have provided strong evidence to support its transcriptional repressor’s role of
Zeb1/TCF8 in EC gene regulation during EC differentiation from hES cells. Data from
loss-of-function gene studies using speciﬁc Zeb1 siRNA pool showed that the knockdown
of endogenous Zeb1 gene expression signiﬁcantly increased EC-speciﬁc gene
expression levels and promoter activity.” Luo et al. Stem Cells 31:1749.
And 
• “Downregulation of Zeb1, a direct target of miR-200 family, and E-CADHERIN, a
target protein of Zeb1, was observed in hESCs during differentiation into endodermal
and mesodermal lineages, respectively.” Kim Y et al Int J Stem Cells. 2017;10:28-37.
Remarkably, our experimental findings are well supported by the two studies mentioned above to 
whom we added additional novel information. We have not clear explanation for the controversy 
or how to reconcile discrepancies among the work of different authors and laboratories. Further 
work is required to solve this matter. It is evident, however, that the experimental cellular models 
adopted in our and Liu’s work are very dissimilar (human vs murine ES) and that the 
pharmacological effect of nitric oxide has not been addressed in the recent Circulation Research 
manuscript making difficult any further comparison. However Liu´s results were commented in 
the Discussion section (Page 14; lines 390-397). 
Q4) Lastly, while the authors now cited the four articles I highlighted in the first review, 
they have not engaged in any meaningful discussion on how these articles relate/overlap 
with their own work.  
A4) As requested new comments have been provided related to the literature in object (ref 6 in 
the Introduction; ref 3 in the Introduction; ref 14 page 14 line 399-403; ref 41 page 13-14 lines 
383-390). 
Q5) I continue to be concerned with the CRISP/Cas9 targeting of Zeb1. In the original 
manuscript (Supplemental Figure 4c) authors failed to obtain an efficient CRISP/Cas9 
targeting of Zeb1 using two independent vectors (GS-LCv2_Zeb1_1 and GS-
LCv2_Zeb1_2). Now (Supplementary Figure 4a) they show that CRIPS/Cas9 targeting has 
abrogated Zeb1 expression but it is not clear whether the CRIPS/Cas9 vector has been 
changed. The authors now referred this vector as LCv2_Zeb1. However, in Methods, the 
authors still mentioned the two vectors used in the original version (GS-LCv2_Zeb1_1 and 
GS-LCv2_Zeb1_2). One has to assume that only one of the original vectors worked. If that 
In that case, it is not clear which of the two vectors is shown in Supplementary Figure 4A 
and used in Figures 3g and 4a. It is not clear which targeting vectors referred in Methods 
are used in the manuscript, why only one of the two (or probably none of them) is shown in 
Suppl Fig 4c, which of the targeting vectors worked or why in Suppl. Fig 4c one of the 
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targeting vectors has been now deleted. In any case, as standard practice (particularly for a 
journal like Nature Communications), at least TWO independent CRIPS/Cas9 targeting 
vectors for Zeb1 should be used, particularly considering that Zeb1 is the main point in the 
title and Abstract.  
A5) All experiments were performed with clones derived from both original vectors generating 
two independent CRISPR/Cas9 Zeb1 gene knockout. In the new version of the manuscript_R2, 
the authors added western blotting depicting the results obtained from both vectors 
(Supplemental figure 4 panel c). The related original nomenclature was restored: LCv2_Zeb1_1; 
LCv2_Zeb1_2; LCv2_Hdac2_1 and LCv2_Hdac2_2. New panels in the supplemental figure 4 
panel c have been added to the supplemental set of revised figures and method section was 
explicated accordingly (Page 26 lines 774-780). The authors apologize for the lack of clarity in 
this matter. 
Q6) Cytoplasmic translocation of Zeb1. In the original version, the authors claimed that in 
Supplemental Figure 2, panel b, Zeb1 “clearly” relocate out the nucleus. A new Supp Fig 2c 
showing Zeb1 expression in cytoplasmic and nuclear fractions has been added. However, 
the authors made no effort to show a more representative immunofluorescence picture. 
Supp Fig 2b continues to be unconvincing at best. In other words, the results in Suppl Fig 
2b and 2c do not match. 
A6) According to Reviewer’ suggestion a new confocal analysis has been performed and a new 
picture has been added to the manuscript (see new supplemental figure 2, panel b). 
Q7) Figure 6e. The Western blot for Zeb1 in ESNO+ has half of the band stronger than the 
other half as if a bubble interfered with the blotting. Another blot should be shown.  
A7) A new and better quality western blot has been provided. See figure 6, panel e. 
Q8) For all the Western blots in the manuscript, full uncut gels should be shown. This a 
standard practice nowadays and it becomes critical in this manuscript where many of the 
blots shown were cut just below/above the band or the bands are not very clear (bottom of 
Fig 3e, Fig 5d, Fig 6a, Supp Fig 1b, Supp Fig 2d, Supp Fig 4a, Supp Fig 5a). Full uncut gels 
should be shown for all Western blots.  
A8) Uncut gels for all the westerns have now been provided as a supplemental set of figures (See 
file named: C Cencioni et al Mechanics of mesendodermal commitment in ground state 
mES_Supplemental full-lenght images of representative WBs_R2). 
Q9) In my first review, I pointed to the need to provide a comprehensive list with the source 
of all the Abs used. This is critical considering that the quality of the Ab used is essential in 
ChIP-seq analysis. The authors indicated that the information has been now included. But 
this reviewer was unable to find (unless I did not get all the manuscript documents) where 
this information has been included. At least, it is not in the section of Methods related to 
Western blot and immunoprecipitation.  
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A9) An updated table with all information about the antibodies used has been added to the 
manuscript (see Table 4). 
REVIEWER 3 
 Reviewer #3 (Remarks to the Author): Cencioni et al. report that endothelial nitric oxide 
synthase (eNOS) is rapidly upregulated in a subpopulation of mouse ES cells upon exit from 
ground state pluripotency in 2i/LIF conditions. This eNOS-positive fraction produces nitric oxide 
(NO), shows elevated expression of mesendodermal genes and more efficiently generates 
embryoid bodies with beating areas. ES cells in which eNOS was disrupted by CRISPR-
mediated gene targeting failed to produce NO or efficiently upregulate mesendodermal genes 
following the withdrawal of 2i/LIF. Mechanistically, NO was shown to inhibit the nuclear 
function of Hdac2 via S-nitrosylation, and to activate the expression of miR-200 miRNAs. Both 
of these events are proposed to antagonize the transcriptional repressor Zeb1, which normally 
suppresses mesendoderm-associated genes including eNOS under ground-state conditions. The 
existence of a feedback circuitry among Zeb1, Hdac2 and eNOS is corroborated by additional 
genetic studies showing that CRISPR-mediated ablation of Zeb1 or Hdac2 in ES cells causes 
premature expression of eNOS and other mesendoderm-associated genes. This manuscript 
uncovers a novel regulatory axis mediating mesendodermal commitment of ground state mouse 
ES cells. Previous work had suggested that low doses of NO delay differentiation (Tejedo et al., 
2010), but this study demonstrates that eNOS/NO promote ES cell differentiation, especially into 
cardiovascular precursors. Overall the manuscript is of interest and appropriate for Nature 
Communications, but the authors should clarify the following points:  
The authors would like to thank the Reviewer for His/Her positive evaluation of their work. The 
following is a point to point letter addressing the specific concerns. 
Q1) ChIP experiments indicate that Zeb1 becomes uncoupled from chromatin at 
mesendodermal target genes in differentiation media, regardless of whether an exogenous 
source of NO is supplied (Figure S3b). However, the induction of mesendodermal target 
genes was far more dramatic in the presence of exogenous NO (Figure S3a). This raises an 
important question which the authors do not comment on: how does exogenous NO further 
boost the expression of mesendodermal genes? Since Zeb1 is already fully uncoupled from 
chromatin in DM alone, there must be some additional mechanism whereby exogenous NO 
promotes mesendodermal commitment that is independent of Zeb1 (see also my next 
point).  
A1) The effect of nitric oxide is epigenetically pleiotropic. In fact, our prior work (Illi et al. 
Pharmacol Ther. 2009;123:344-52) summarizes the properties of NO in terms of class I Hdac 
regulation as well as activator of protein phosphatases 2A (PP2A) (see also Illi et al. Circ Res. 
2008;102:51-8; ref 17). Indeed, PP2A is involved in the regulation of class II HDACs whose 
activation and nuclear translocation is important for the mesendodermal commitment of mES as 
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reported previously in our work from Spallotta et al Stem Cells. 2010;28:431-42 (ref 6). 
Moreover, NO is able to induce miR-200 family, an additional mechanism whereby exogenous 
NO contributes to mesendodermal differentiation of mES (Rosati et al ATVB 2011;31(4):898-
907; ref 5). Mora-Castilla et al demonstrated that NO represses stemness marker genes such as 
Nanog and Oct4 as consequence of an increase in H3 trimethylation and an enhancement of 
pSer315 p53 (Cell Death Diff 2010;17:1025-33; ref 3). Furthermore, NO dependent increase of 
cGMP is able to increase the expression of cardiovascular markers like Nkx2.5 and myosin light 
chain (PNAS 2008;105:18924-29; ref 4). It is therefore well conceivable that additional 
mechanisms will take place during the NO-dependent regulation of gene expression occurring in 
differentiating mES. A new comment about this important aspect has been added in the 
Discussion of the revised manuscript version (pages 14, lines 397-422).        
Q2) The authors propose two distinct mechanisms for NO-dependent regulation of 
mesendodermal target genes: S-nitrosylation of Hdac2, which leads to nuclear export of 
Zeb1, and activation of miR-200b, which inhibits Zeb1 translation. While inhibition of 
miR-200b abrogates NO-dependent activation of several mesendoderm-associated genes, 
the activation of Wnt3 and Tbx4 was notably less affected (Figure S3c). Interestingly, these 
two mesendodermal targets were not induced in Zeb1-KO ES cells cultured with exogenous 
NO (Figure 4a), but they were highly induced in Hdac2-KO ES cells cultured in the same 
condition (Figure 4b). These observations suggest that Hdac2 mediates transcriptional 
repression at a subset of mesendodermal targets, such as Wnt3 and Tbx3, independently of 
Zeb1. Have the authors considered the possibility of such a Zeb1-independent role of 
Hdac2? 
A2) Following Reviewer’ suggestion we now explored the enrichment of Hdac1, Hdac2 on the 
promoter of our gene signature and found that Zeb1, Hdac1 and Hdac2 similarly detached from 
target chromatin regions when cells were released from stemness or exposed to the NO donor. 
This evidence does not allow to assign Hdac2 alone a role in the regulation of Wnt3 or Tbx4 
clearly distinct from that of Zeb1. Hence, the apparent positive consequence of Hdac2 
inactivation on the expression of those two target genes must imply additional mechanisms 
possibly associated to the structure of their promoter and the recruitment of gene-specific 
transcription factors. The new data (Supplemental figure 3, panel d) and a comment have been 
added to the Results section of the revised manuscript (page 10 lines 261-266).  
Q3) As a general point, I wonder how representative the experiments with an exogenous 
source of NO are for the endogenous activation of eNOS/NO that occurs during ES cell 
differentiation. Can the authors directly compare the levels of NO under these two 
experimental conditions?  
A3) A new experiment has been performed addressing this specific issue. Supplemental figure 4, 
left panel a shows that in the presence of the NO donor DETANO a higher number of mES 
became DAF positive compared to cells released from stemness in the absence of an exogenous 
source of NO. The experiment however shows that during time-course the dynamics of NO signal 
was nearly similar in both conditions reaching a peak at 2 hours and declining with a similar 
fashion in the first 24 hours from induction. Interestingly, evaluation of the mean fluorescence 
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intensity (MFI) revealed no significant differences between the two populations in spite of the 
presence of the NO donor. This result, shown in figure 4 right panel a indicated that, in our 
experimental conditions, the global intracellular content of NO was similar in cells released 
from stemness in the presence or absence of NO. In summary, the NO donor increases the total 
number of DAF-positive cells however does not significantly affect the fluorescence intensity 
derived from the NO-dependent activation of DAF reporter probe. A comment about these new 
data has been added to the Result section of the revised manuscript version (page 10 lines 275-
279). 
Q4) In addition, does the DAF+ subpopulation shown in Figure 6b have increased S-
nitrosylation of Hdac2 (as was shown in Figure 3c in presence of exogenous NO)?  
A4) A new experiment has been performed addressing this point. Figure 6 panel f shows that 
sorted ESNO+ cells present a significantly higher content of nitrosylated Hdac2 compared to 
ESNO- cells. This evidence reinforces the role of Hdac2 nitrosylation in the commitment of 
ESNO+ cells to mesendodermal differentiation. This result has been added to the revised Results 
section (page 13 lines 360-361) and commented into Discussion (page 17 lines 508-511). 
Minor points: 
1. Throughout the manuscript CRISPR-targeted ES cell lines should be referred to as
knockout, rather than knockdown clones. The term “knockdown” is typically used
to denote RNAi studies where only partial downregulation of the target gene is
achieved.
Manuscript has been amended as indicated. 
2. Please add in-figure labels to the ChIP-Seq tracks in Figure 2b and Figure S4b.
Labels have been added as requested. 
Reviewer #3 (Remarks to the Author): 
The authors have provided detailed answers to the reviewers’ questions and have 
performed additional experiments. However, I still have a number of concerns:  
1. The authors have added Hdac1/2 ChIP experiments to Supplemental Figure 3c-d. These
experiments show that, as noted for Zeb1 (Supplemental Figure 3b), Hdac1/2 becomes 
decoupled from chromatin at mesendoderm target genes upon switch to differentiation 
medium (DM), regardless of the presence of exogenous NO. However, with the exception of 
Dll1, most upregulation of mesendoderm target genes only occurred when DM was 
supplemented with exogenous NO (Supplemental Figure 3a). Thus, some mechanism other 
than Zeb1 or Hdac1/2 decoupling from these targets is responsible for stimulating these 
mesendodermal genes in the presence of NO. Another possibility is that Zeb1 or Hdac1/2 
indirectly regulate these target genes by repressing an as-yet-unidentified transcriptional 
activator. As currently presented, this dataset is problematic because it does not support 
the authors’ central argument that NO directly relieves the repression of mesendodermal 
genes by evicting Zeb1 and Hdac1/2 from chromatin at these particular loci. The authors do 
not directly comment on this issue in their revised manuscript. It may be possible to identify 
target genes that specifically lose Zeb1 or Hdac1/2 binding upon exposure to NO by 
performing ChIP-Seq for Zeb1 or Hdac1/2 in DM ± NO.  
2. Following on the previous point, the authors should be careful throughout their study to
distinguish between those effects mediated specifically by exposure to NO vs. effects that 
arise simply from the switch to DM. For example, Fig. 1c highlights differentially expressed 
genes (DEGs) between mESCs maintained in 2i/LIF (GS) vs. mESCs exposed to DM with 
exogenous NO. However, to determine the response to NO, it would be more appropriate to 
focus on DEGs in DM ± NO. Similarly, the “NO up-genes” shown in Fig. 2a currently also 
include genes that are upregulated in DM alone, i.e. without exogenous NO.  
3. In several panels the authors compare mRNA expression levels of five mesendodermal
genes in mESCs in GS vs. 24h after exposure to DM or NO. However, the mRNA fold 
increases in Supplementary Figure 3a are much greater than those shown in Supplementary 
Figure 3e or Figure 4a-b. For example, Tbx4 was induced ~500-fold after 24h of NO 
treatment in Supplementary Figure 3a, but Tbx4 upregulation was only ~20-fold in 
Scramble-LNA control cells (Supplementary Figure 3e) or LCv2_NTC control cells (Figure 4a) 
at the same timepoint relative to GS. How do the authors explain these differences?  
4. Some paragraphs are currently too long and contain too many details, which makes the
paper inaccessible to a general audience. I recommend introducing line breaks at the 
following positions to split up the long paragraph in the Results section on p.9: lines 229-
230 (start a new paragraph with “To investigate whether Zeb1 could be involved….”) and 
lines 253-254 (start a new paragraph with “The expression of the most represented NO-
Zeb1-dependent genes…”).  
5. The manuscript must be properly edited to improve English grammar and spelling. The
Discussion alone contained the following obvious typos: “heterogeinicity” (line 396), 
“hypotesize" (line 435), “trascription factor” (line 439), “repression transcription factor” 
(line 439, I suggest “repressive”), “metastatization” (line 464). The authors should also 
avoid terms like “stemness” (abstract, line 58) or “stemmed out” (Discussion, line 382), 
which are not very specific and instead refer to “self-renewal” or “pluripotency”, where 
appropriate. The abbreviation “mES” is used throughout the text, but “ESC” or “ES cells” are 
more commonly used abbreviations.  
The authors would like to thank the Editor and the Reviewer for their positive comments to our work. 
Reviewer #3: 
Q1. The authors have added Hdac1/2 ChIP experiments to Supplemental Figure 3c-d. These 
experiments show that, as noted for Zeb1 (Supplemental Figure 3b), Hdac1/2 becomes 
decoupled from chromatin at mesendoderm target genes upon switch to differentiation medium 
(DM), regardless of the presence of exogenous NO.  
A1. We would like to thank the Reviewer for His/Her valuable comment. We understand that our 
data may not be easily interpreted as a consequence of lack of representation clarity. In our 
experiments mouse ESC begin synthesizing nitric oxide as soon as two hours after changing culture 
condition from self-renewal to differentiation (see Fig. 3a and Fig. 6b and suppl. Fig. 4a below and 
in the manuscript body). Hence, it may be unfeasible to fully separate the biological effect of DM 
“per se” from the culture medium supplemented with exogenous NO. In this condition, the 
evaluation of spontaneous production of NO has been one of the goals of our work that revealed, 
for the first time, the presence of a new mouse ESC sub-population spontaneously synthesizing NO 
upon release from pluripotency (See Fig. 6b below and in the manuscript body).  Noteworthy, as 
requested by this Reviewer, in the revised manuscript version we were able to assess that the 
intensity of NO production from the endogenous cell population was similar to that obtained by 
addition of the exogenous source of NO (See suppl. Fig. 4a below and in the body of the 
manuscript). 
Fig 3a. The graph shows the results of cGMP intracellular level quantification in mES cultured 24 h in GS (black bar), 30 
min,  1h, 2h or 3h in DM alone or in the presence of PTIO, ODQ, L-NAME (gray bars) and 24h in NO alone or in the 
presence of PTIO (white bars), as indicated. Represented data are the mean of three independent experiments ± s.e.m. 
(*p < 0.05 DM vs GS; °p < 0.05 treatments vs DM). 
Fig 6b. Left cytogram: representative scatter plot showing FSC-A and SSC-A distribution of the mESC population cultured 
in DM for 2 h in the presence of the DAF fluorescent probe. Right cytogram: representative dot plot showing the FITC and 
SSC-A distribution of the mESC population cultured in DM for 2 h in the presence of the DAF fluorescent probe. In each 
experiment, gating to separate ESNO+ (DAF+; blue dots) from ESNO- (DAF-; red dots) cells was established manually 
(n=3). 
 
Suppl fig 4a. Left panel: percentage of DAF positive mESC cultured 1, 2, 3, 6 and24 h in DM or NO revealed by FACS 
analysis. Data are represented as mean±s.e.m. (n=3; *p<0.05 vs DM). Right panel: DAF mean fluorescence intensity (MFI) 
measured by FACS analysis in mESC cultured 1, 2, 3, 6 and 24 h in DM or NO. Data are represented as mean±s.d. (n=3). 
 
Q2. However, with the exception of Dll1, most upregulation of mesendoderm target genes only 
occurred when DM was supplemented with exogenous NO (Supplemental Figure 3a). Thus, some 
mechanism other than Zeb1 or Hdac1/2 decoupling from these targets is responsible for 
stimulating these mesendodermal genes in the presence of NO. 
 
A2. The authors apologize for the lack of clarity regarding their data representation in suppl. Fig. 3a. 
In the revised version of suppl. Fig. 3a (see below), the y axes has been now divided into two 
segments, making more easily  noticeable that not only Dll1 gene increases in DM condition but also 
other members of the signature, including Wnt3, Wnt7b, Tbx4 and Mesp2. Furthermore, the NO 
synthesis inhibitor L-NAME added in DM reduced mesendodermal gene expression as compared to 
DM alone (see suppl. Figure 4d below and in the manuscript version). This observation is paralleled 
by the experimental evidence provided in Fig. 3b (see below and in the manuscript body) in which 
the NO scavenger PTIO fully reversed Zeb1 binding to signature gene chromatin. In line with the 
above evidence, an independent series of experiments performed by using a constitutively active 
eNOS mutant (eNOSS1177D) showed that the signature genes became already detectable in ground 
state condition further indicating that NO synthesis controls their expression (see Fig. 5e below and 
in the manuscript body). In the same condition, Hdac2 was found nitrosylated (See Fig.5d below and 
in the manuscript body).    
To further clarify the point raised by Reviewer a new set of experiments has been performed in 
which we were also able to evaluate that, in the presence of PTIO, the expression of our signature 
genes was significantly prevented in spite of the release of mESC from pluripotency (see fig. below 
that can be provided in a revised version of the manuscript as new suppl. Fig. 3b). 
 
New Suppl fig 3a. mRNA expression analysis of Wnt3, Wnt7b, Tbx4, Dll1 and Mesp2 in mES cultured 24 h in GS (black 
bars), DM (grey bars) or NO (white bars). Data are represented as mean fold increase ±s.e.m. compared to GS after 
subtraction of the housekeeping gene p0 signal (n=5; *p < 0.05 vs. GS; °p < 0.05 vs. DM). 
 
Suppl fig 4d. mRNA expression analysis of eNOS, Wnt3, Dll1 and Wnt7b in mESC cultured 24 h in GS (black bars), DM 
(grey bars), DM + L-NAME (gray striped bars), DM + ODQ (gray squared bars) and NO (white bars). Data are represented 
as mean fold increase ±s.e.m. compared to GS after subtraction of the housekeeping gene p0 signal (n=4; *p < 0.05 vs. 
GS; #p < 0.05 vs. DM). 
 
 Fig 3b. ChIP/qRT-PCR analysis of Zeb1 chromatin binding on nitric oxide-dependent mesendodermal genes: Wnt3, 
Wnt7b, Tbx4, Dll1 and Mesp2. Chromatins were extracted from mESC culture 24h in DM alone (gray bars) or in the 
presence of PTIO (striped bars). Data are shown as mean fold increase ±s.e.m. compared to IgG value (striped bars) after 
Input normalization (n=3). 
 
Fig 5e. qRT-PCR analysis of mRNA expression relative to the Wnt3, Wnt7b, Tbx4, Dll1 and Mesp2 transcripts in mESC 
cultured for 24h in GS prior (control Adeno virus Ad_GFP; black bar) and after infection by Ad_eNOSwt (gray bars) or 
Ad_eNOSS1177D expressing the constitutive active eNOS (white bars). Data are shown as the mean of three independent 
experiments ± s.e.m. represented as fold increase compared to Ad-GFP infected mESC after subtraction of the 
housekeeping gene p0 signal (*p < 0.05 vs Ad_GFP). 
 
Fig 5d. Representative immunoprecipitation (IP) western blotting (WB) analysis of Hdac2 S-nitrosylation performed in 
mES infected by Ad_GFP, Ad_eNOSwt or Ad_eNOSS1177D cultured in GS or after 2h from release into DM (n=3 each 
group). 
 
New Suppl Fig 3b. mRNA expression analysis of Wnt3, Wnt7b, Tbx4, Dll1 and Mesp2 in mESC cultured 24 h in GS (black 
bars), DM (grey bars), DM + PTIO (gray striped bars). Data are represented as mean fold increase ±s.e.m. compared to GS 
after subtraction of the housekeeping gene p0 signal (n=4). 
 
Q3. Another possibility is that Zeb1 or Hdac1/2 indirectly regulates these target genes by 
repressing an as-yet-unidentified transcriptional activator. As currently presented, this dataset is 
problematic because it does not support the authors’ central argument that NO directly relieves 
the repression of mesendodermal genes by evicting Zeb1 and Hdac1/2 from chromatin at these 
particular loci. The authors do not directly comment on this issue in their revised manuscript.  
 
A3. We thank the Reviewer for His/Her suggestion. We will add a paragraph in the Discussion 
section exploiting the possibility that an additional indirect mechanism could be involved in the 
regulation of mesendodermal genes. However, we would like to stress here that our central 
argument about the NO-dependent eviction of Zeb1 and Hdac1/2 from chromatin is still standing. In 
fact, this mechanism seems to play an important role in the activation of the mesendodermal 
transcription program described in our manuscript. Specifically, the following experimental 
evidences substantiate our conclusion: 
1. Treatment with PTIO in DM condition rescued Zeb1 binding to chromatin at the mesendodermal 
loci (see again Fig. 3b below).  
2.  Hdac2 appears significantly nitrosylated as soon as mouse ESC are released from pluripotency 
(see Fig. 3c below and in the body of the manuscript) or in the presence of a constitutively active 
eNOS mutant (see Fig. 5d below and in the body of the manuscript) as apparent direct consequence 
of the endogenous NO production. As previously reported this modification prevents Hdac2 from 
chromatin binding (see references 18 and 19 in the manuscript: 18. Nott, A. et al. S-nitrosylation of 
HDAC2 regulates the expression of the chromatin-remodeling factor Brm during radial neuron 
migration. Proc Natl Acad Sci U S A 110, 3113-3118 (2013); 19. Nott, A., Watson, P.M., Robinson, 
J.D., Crepaldi, L. & Riccio, A. S-Nitrosylation of histone deacetylase 2 induces chromatin remodelling 
in neurons. Nature 455, 411-415 (2008)). 
3. The knockout of Zeb1 by CRISPR/Cas9 technology promoted the expression of the signature genes 
already in cells cultured in ground state thus bypassing the repression effect of the 2i/L condition 
(See Fig. 4a below and in the manuscript body). 
4. On the contrary, Zeb1 overexpression counteracted the effect of NO on the expression of the 
signature genes (see suppl. Fig 5a and b below and in the manuscript body). 
5. The genetic inactivation of eNOS prevented the expression of the signature genes after mESC 
release from pluripotency (see Fig. 5b below and in the manuscript body).   
 
Fig 3b. ChIP/qRT-PCR analysis of Zeb1 chromatin binding on nitric oxide-dependent mesendodermal genes: Wnt3, Wnt7b, 
Tbx4, Dll1 and Mesp2. Chromatins were extracted from mESC culture 24h in DM alone (gray bars) or in the presence of 




Fig 3c. Left panel: representative immunoprecipitation (IP) western blotting (WB) analysis of Hdac2 S-nitrosylation 
performed in mESC cultured in GS (24h) or after 2h from release into DM or NO. Right panel: the bar graph shows the 
mean result of relative densitometric analysis obtained from three independent experiments ± s.e.m. (*p < 0.05 NO vs 
DM). 
 
Fig 5d. Representative immunoprecipitation (IP) western blotting (WB) analysis of Hdac2 S-nitrosylation performed in 




Fig 4a. qRT-PCR analysis of mRNA expression relative to the Wnt3, Wnt7b, Tbx4, Dll1 and Mesp2 transcripts in mES 
cultured for 24h in GS, DM and NO prior (control vector LCv2_NTC; black bar) and after CRISPR/Cas9 inactivation of Zeb1 
(LCv2_Zeb1_1/_2; gray bars). Data are shown as the mean of three independent experiments for each CRISPR/Cas9 
vector ± s.e.m. represented as fold increase compared to control mES after subtraction of the housekeeping gene p0 
signal (*p < 0.05 LCv2_Zeb1_1/_2 vs LCv2_NTC). 
 
Suppl fig 5. Zeb1 overexpression contrasts mesendoermal marker expression in released mESC. (a) Representative 
western blotting analysis of cell extracts obtained from mESC after infection with lentivirus expressing GFP (Lenti_Empty) 
or Zeb1 (Lenti_Zeb1) cultured 24 h in GS, DM and NO probed with Zeb1 antibody. For each extract, α-tubulin was used as 
loading control. The experiment was repeated three times. (b) mRNA expression analysis of Wnt3, Wnt7b, Tbx4, Dll1 and 
Mesp2 in mESC after infection with lentivirus expressing GFP (Lenti_Empty) or Zeb1 (Lenti_Zeb1) cultured 24 h in GS, DM 
and NO. Data are represented as mean fold increase ±s.e.m. compared to GS_Lenti_Empty after subtraction of the 
housekeeping gene p0 signal (n=3; *p < 0.05 vs. GS_Lenti_Empty; °p < 0.05 vs. Lenti_Empty). 
 
Fig 5b. qRT-PCR analysis of mRNA expression relative to the Wnt3, Dll1, Wnt7b, Mesp2, and Tbx4 transcripts in mESC 
cultured for 24 h in GS and DM prior (control vector LCv2_NTC; black bar) and after CRISPR/Cas9 inactivation of eNOS 
(LCv2_eNOS_1/_2; gray bars). Data are shown as the mean of three independent experiments for each CRISPR/Cas9 
vector ± s.e.m. represented as fold increase compared to control mESC after subtraction of the housekeeping gene p0 
signal (*p < 0.05 DM vs GS; °p < 0.05 LCv2_eNOS_1/_2 vs LCv2_NTC). 
 
Q4. It may be possible to identify target genes that specifically lose Zeb1 or Hdac1/2 binding 
upon exposure to NO by performing ChIP-Seq for Zeb1 or Hdac1/2 in DM ± NO.  
 
A4. In light of our data and considering the comments listed above the requested ChIP-seq analyses 
may not be technically feasible due to intrinsic limitations of the system. Specifically, in the 
differentiation medium with NO, one of the experimental condition requested by this Reviewer, the 
level of Zeb1 is barely detectable (see suppl. Fig. 2a-c below and in the manuscript body). Similarly, 
already in DM alone, Hdac2 appears nitrosylated and possibly inactivated by detachment from 
chromatin (see Fig. 3c and old Suppl. fig 3d (now Suppl. Fig. 3e) respectively; below and in the 
manuscript body). Therefore it may be difficult to perform additional ChIP-seq analyses in the virtual 
absence of Zeb1 or Hdac2 from chromatin. Technically, in fact, in the presence of a reduced content 
of a chromatin-associated factor the efficiency of the chromatin-immunoprecipitation may decrease 
significantly preventing the sequencing reaction from performing efficiently with consequences on 
the number of reads and final data interpretation. For this reason we decided to utilize the more 
sensitive qPCR approach to reveal differences in Zeb1 or Hdac2 binding on the mesendodermal 
genes object of interest in this study.  
 
Suppl fig 2.  Zeb1 regulation in naïve and differentiating mESC. (a) Representative western blotting analysis of cell 
extracts obtained from mESC cultured 24h in SM, DM and NO (left panel) and GS, DM and NO (right panel) probed with 
Zeb1 antibody. For each extract, α-tubulin was used as loading control. The experiment was repeated three times. Right 
panels show the result of densitometric analysis (*p < 0.05 vs. stemness condition). (b) Representative confocal 
microscopy images depicting mESC cultured 24h in GS, DM or NO. Cells were probed by an anti-Zeb1 antibody (green; 
upper panels). Nuclei were counterstained with TROPRO 3 (blue; middle panels). Merged fluorescence images are shown 
in the lower panels. On the right, the insets contain enlargements of the selected areas (dashed squares). Magnification 
40x. (c) Representative western blotting analysis of cytoplasm/nuclear fractionation extracts obtained from mESC 
cultured 24h in GS, DM or NO probed with Zeb1. For cytoplasmic extracts, α-tubulin was used as a loading control, 
whereas for nuclear extracts Fibrillarin and H3 were used as loading control. The experiment was repeated three times. 
 
Fig 3c. Left panel: representative immunoprecipitation (IP) western blotting (WB) analysis of Hdac2 S-nitrosylation 
performed in mESC cultured in GS (24h) or after 2h from release into DM or NO. Right panel: the bar graph shows the 
mean result of relative densitometric analysis obtained from three independent experiments ± s.e.m. (*p < 0.05 NO vs 
DM). 
 
Suppl fig 3d-now Suppl fig 3e. ChIP/qRT-PCR of Hdac2 chromatin association on the promoter regions of Wnt3, Wnt7b, 
Tbx4, Dll1 and Mesp2. Chromatins were extracted from mESC cultured 24 h in GS (black bars), DM (grey bars) or NO 
(white bars). Data are shown as mean fold increase ±s.e.m. compared to IgG value after Input normalization. Three 
independent experiments were performed. 
 
Q5. Following on the previous point, the authors should be careful throughout their study to 
distinguish between those effects mediated specifically by exposure to NO vs. effects that arise 
simply from the switch to DM. For example, Fig. 1c highlights differentially expressed genes 
(DEGs) between mESCs maintained in 2i/LIF (GS) vs. mESCs exposed to DM with exogenous NO. 
However, to determine the response to NO, it would be more appropriate to focus on DEGs in 
DM ± NO. Similarly, the “NO up-genes” shown in Fig. 2a currently also include genes that are 
upregulated in DM alone, i.e. without exogenous NO.  
 
A5. We thank the Reviewer for the interesting suggestion He/She raised in this revision. However, 
we must stress that our major interest here has been to investigate at molecular level the effect of 
NO in mESC, without distinguishing between endogenous production and exogenous 
administration. This line of research led to the identification of a NO positive cell sub-population 
recognized by NO production and mesendodermal gene expression already detectable in DM 
condition. The reason why some “NO up-genes” are upregulated already in DM is possibly 
ascribable to the endogenous production of NO as demonstrated by the L-NAME experiments 
shown in suppl. Fig. 4d (see below and in the manuscript body). In addition, the new data 
represented below indicate that the NO scavenger PTIO significantly reduces the expression of the 
signature genes in mESC released from pluripotency further corroborating the hypothesis that NO 
could play an important role in the mesendodermal differentiation program of these cells. However, 
following this reviewer suggestion new bioinformatics and gene ontology analyses were performed 
on DEGs observed in NO vs DM. These results (see below) indicate that no clear pattern of 
differentiation lineage emerges from this comparison. Specifically apoptotic cell death pathways 
seem among the most upregulated ones while mixed neuroectodermal pathways are detectable 
among those underrepresented (see figure below). In light of these considerations, the authors feel 
that, although very important, the investigation of NO vs DM genes is more matter for future 
developments than object of specific attention at the present time. 
 
Suppl fig 4d. mRNA expression analysis of eNOS, Wnt3, Dll1 and Wnt7b in mESC cultured 24 h in GS (black bars), DM 
(grey bars), DM + L-NAME (gray striped bars), DM + ODQ (gray squared bars) and NO (white bars). Data are represented 
as mean fold increase ±s.e.m. compared to GS after subtraction of the housekeeping gene p0 signal (n=4; *p < 0.05 vs. 
GS; #p < 0.05 vs. DM). 
 
New Suppl Fig 3b. mRNA expression analysis of Wnt3, Wnt7b, Tbx4, Dll1 and Mesp2 in mESC cultured 24 h in GS (black 
bars), DM (grey bars), DM + PTIO (gray striped bars). Data are represented as mean fold increase ±s.e.m. compared to GS 
after subtraction of the housekeeping gene p0 signal (n=4). 
Left panel: MA plot of differentially regulated genes (DEGs) expressed in mESC cultured for 24h in NO compared to DM 
condition. Red dots show genes with a padj < 0.05. Right panels: Gene ontology analysis of DEG between mESC cultured 
in NO and DM. Up-regulated genes depicted in the upper panel, red bar graph; down-regulated genes in the lower panel, 
blue bar graph. 
Q6. In several panels the authors compare mRNA expression levels of five mesendodermal genes 
in mESCs in GS vs. 24h after exposure to DM or NO. However, the mRNA fold increases in 
Supplementary Figure 3a are much greater than those shown in Supplementary Figure 3e or 
Figure 4a-b. For example, Tbx4 was induced ~500-fold after 24h of NO treatment in 
Supplementary Figure 3a, but Tbx4 upregulation was only ~20-fold in Scramble-LNA control cells 
(Supplementary Figure 3e) or LCv2_NTC control cells (Figure 4a) at the same timepoint relative to 
GS. How do the authors explain these differences?  
A6. We thank the Reviewer for pointing out this aspect. However we do not have a clear 
explanation for the diverse intensity of the responses observed for the same genes in the different 
experimental settings. We may only argue that in suppl. figure 3a cells were not significantly 
manipulated before assay while in suppl. Fig. 3e as well as in Fig. 4a-b cells underwent different 
treatments or rounds of selections. Specifically the results displayed in suppl. Fig. 3e were obtained 
after nucleofection while for those represented in figure 4a-b nucleofected and puromycin selected 
mESC were used. These specific manipulations may have affected the intensity of the response 
although no consequences were observed on the experimental trend of the biological effect. 
Statements specifying the different experimental conditions are present in the legend of suppl. 
figure 3e and/or in methods. 
Q7. Some paragraphs are currently too long and contain too many details, which makes the 
paper inaccessible to a general audience. I recommend introducing line breaks at the following 
positions to split up the long paragraph in the Results section on p.9: lines 229-230 (start a new 
paragraph with “To investigate whether Zeb1 could be involved….”) and lines 253-254 (start a 
new paragraph with “The expression of the most represented NO-Zeb1-dependent genes…”).  
A7. Manuscript can be edited according to Reviewer’s suggestion. 
 
Q8. The manuscript must be properly edited to improve English grammar and spelling. The 
Discussion alone contained the following obvious typos: “heterogeinicity” (line 396), 
“hypotesize" (line 435), “trascription factor” (line 439), “repression transcription factor” (line 
439, I suggest “repressive”), “metastatization” (line 464). The authors should also avoid terms 
like “stemness” (abstract, line 58) or “stemmed out” (Discussion, line 382), which are not very 
specific and instead refer to “self-renewal” or “pluripotency”, where appropriate. The 
abbreviation “mES” is used throughout the text, but “ESC” or “ES cells” are more commonly used 
abbreviations. 
 




Additional comments from reviewer #3:  
 
I think the authors have offered a clear response to my questions. Their new data clarify that nitric 
oxide indeed triggers the eviction of Zeb1 and Hdac from chromatin, resulting in the upregulation of 
mesendodermal genes in embryonic stem cells. Therefore, I think they should be given an opportunity 
to resubmit a revised version of manuscript, provided that they include all of the new data and 
discussion points that are mentioned in the rebuttal.  
 
Their revision should also address the following two points:  
 
1) New Supplemental Figure 3a shows that mesendodermal transcripts are upregulated in 
differentiation medium, but much more significantly in the presence of exogenous NO. Therefore, the 
authors should acknowledge that exogenous NO seems to exert additional stimulation of 
mesendodermal target genes via mechanisms that are independent of Zeb1 or Hdac. At present the 
Discussion only mentions in passing that "NO donors are pleiotropic players" (p. 14) without directly 
referring to these data.  
 
2) The new bioinformatic analysis comparing expression in NO vs. DM (Rebuttal, Answer #5) suggests 
that exogenous NO downregulates genes associated with neural development. This is an interesting 
finding and suggests that NO may also promote mesendodermal differentiation by blocking transition 
to alternative cell fates.  
Q2. New Supplemental Figure 3a shows that mesendodermal transcripts are upregulated in 
differentiation medium, but much more significantly in the presence of exogenous NO. 
Therefore, the authors should acknowledge that exogenous NO seems to exert additional 
stimulation of mesendodermal target genes via mechanisms that are independent of Zeb1 or 
Hdac. At present the Discussion only mentions in passing that "NO donors are pleiotropic 
players" (p. 14) without directly referring to these data. 
A2. We thank the reviewer for His/Her valuable suggestion. A paragraph has been added in the 
Discussion section showing/recognizing the contribution of exogenous NO to exert increased 
induction of mesendodermal target genes in the revised manuscript (pages 12-13 lines 343-362). 
Q3. The new bioinformatic analysis comparing expression in NO vs. DM (Rebuttal, Answer #5) 
suggests that exogenous NO downregulates genes associated with neural development. This is an 
interesting finding and suggests that NO may also promote mesendodermal differentiation by 
blocking transition to alternative cell fates. 
A3. The new bioinformatics analysis derived from NO/DM comparison has been added to the 
revised manuscript as Supplementary Fig.2 and exploited to further confirm that NO favours 
mesendodermal differentiation by preventing the transition to alternative cell fates like 
neuroectodermal one. This evidence has been commented at pages 7-8 line 187-189 of the present 
version of the manuscript. 
Additional comments from reviewer #3: 
Q1. I think the authors have offered a clear response to my questions. Their new data clarify that 
nitric oxide indeed triggers the eviction of Zeb1 and Hdac from chromatin, resulting in the 
upregulation of mesendodermal genes in embryonic stem cells. Therefore, I think they should be 
given an opportunity to resubmit a revised version of manuscript, provided that they include all 
of the new data and discussion points that are mentioned in the rebuttal. 
A1. The authors would like to thank the Reviewer for His/Her positive evaluation to their point-to-
point letter. New data are provided as Supplementary Fig. 2; new version of Supplementary Fig. 4a; 
and Supplementary Fig.4b, respectively. Related results have been described in the Result section 
and commented in the Discussion of the revised manuscript (pages 7-9 lines 178-189 and 230-288; 
pages 12-13 lines 351-363). All discussion points mentioned in the rebuttal letter have been included 
in the present version of the manuscript (pages 12-13) 
